logo

Motif Bio Plc (MTFB)



Trade MTFB now with
  Date
  Headline
9/25/2018 2:19:27 AM Motif Bio HY Net Loss US$7.8 Mln Vs. US$29.7 Mln Prior Year
8/14/2018 2:12:30 AM Motif Bio Reports FDA Acceptance Of NDA With Priority Review For Iclaprim
7/3/2018 2:03:04 AM Motif Bio: Robert Bertoldi To Resign From Board
6/14/2018 2:22:09 AM Motif Bio Submits NDA For Iclaprim
6/11/2018 2:01:37 AM Motif Bio Presents New Iclaprim Data At ASM Microbe 2018
5/9/2018 2:11:02 AM Motif Bio Names Stephanie Noviello VP, Clinical Development
5/1/2018 2:13:39 AM Motif Bio Says Iclaprim Met The Primary Endpoint In REVIVE-2 Phase 3 Study
4/10/2018 2:15:36 AM Motif Bio 2017 Net Loss $44.8 Mln Or $0.19/shr Vs. Net Loss Of $40.3 Mln Or $0.35/shr Prior Year
3/20/2018 3:04:35 AM Motif Bio Now Expects To Submit NDA To FDA For Iclaprim During Q2 Of 2018
1/19/2018 2:09:31 AM Motif Bio Announces Filing Of U.S. Shelf Registration